

Initial Prior Authorization with Quantity Limit

Bondlido, Lidoderm, ZTLido

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Bondlido	lidocaine topical system 10%
Lidoderm	lidocaine patch 5%
ZTLido	lidocaine topical system 1.8%

Indications

FDA-approved Indications

Bondlido

Bondlido (lidocaine topical system 10%) is indicated in adults for relief of pain associated with postherpetic neuralgia (PHN).

Lidoderm

Lidoderm is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.

ZTLido

ZTLido (lidocaine topical system) 1.8% is indicated for relief of pain associated with post-herpetic neuralgia (PHN) in adults.

Compendial Uses

Pain associated with diabetic neuropathy⁴

Pain associated with cancer-related neuropathy^{4,5}

Coverage Criteria

Pain Associated with Cancer-Related Neuropathy

Authorization may be granted when the requested drug is being prescribed for pain associated with cancer-related neuropathy (including treatment-related neuropathy [e.g., neuropathy associated with radiation treatment or chemotherapy]).

Pain Associated with Diabetic Neuropathy

Authorization may be granted when the requested drug is being prescribed for pain associated with diabetic neuropathy.

Pain Associated with Post-Herpetic Neuralgia

Authorization may be granted when the requested drug is being prescribed for pain associated with post-herpetic neuralgia.

Continuation of Therapy

Pain Associated with Cancer-Related Neuropathy

Authorization may be granted when the requested drug is being prescribed for pain associated with cancer-related neuropathy (including treatment-related neuropathy [e.g., neuropathy associated with radiation treatment or chemotherapy]) when the following criteria is met:

- The patient has achieved or maintained a positive clinical response to the requested drug.

Pain Associated with Diabetic Neuropathy

Authorization may be granted when the requested drug is being prescribed for pain associated with diabetic neuropathy when the following criteria is met:

- The patient has achieved or maintained a positive clinical response to the requested drug.

Pain Associated with Post-Herpetic Neuralgia

Authorization may be granted when the requested drug is being prescribed for pain associated with post-herpetic neuralgia when the following criteria is met:

- The patient has achieved or maintained a positive clinical response to the requested drug.

Quantity Limits Apply

The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

The duration of 21 days is used for a 28-day fill period and 63 days is used for an 84-day fill period to allow time for refill processing.

Drug	1 Month Limit	3 Month Limit
Bondlido (lidocaine topical system 10%)	56 patches / 21 days	168 patches / 63 days
Lidoderm (lidocaine patch 5%)	90 patches / 25 days	270 patches / 75 days
ZTLido (lidocaine topical system 1.8%)	90 patches / 25 days	270 patches / 75 days

Duration of Approval (DOA)

- 125-C: Initial therapy DOA: 3 months; Continuation of therapy DOA: 36 months
- 1182-C: Initial therapy DOA: 3 months; Continuation of therapy DOA: 12 months

References

- Bondlido [package insert]. Irvine, CA: MEDRx USA, Inc.; September 2025.
- Lidoderm [package insert]. San Jose, CA: TPU Pharma, Inc.; December 2022.
- ZTLido [package insert]. Palo Alto, CA: Scilex Pharmaceuticals Inc.; April 2021.
- Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025.
<https://online.lexi.com>. Accessed October 01, 2025
- Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at:
<https://www.micromedexsolutions.com/> (cited: 10/01/2025).

Reference number(s)
1182-C, 125-C

6. National Comprehensive Cancer Network (NCCN) Guidelines: Adult Cancer Pain V2.2025. National Comprehensive Cancer Network. Available from URL: www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed September 11, 2025.